{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:25:09Z","timestamp":1784633109651,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T00:00:00Z","timestamp":1400630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["currenttherapeuticres.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.curtheres.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T14:45:23Z","timestamp":1411829123000},"page":"64-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers"],"prefix":"10.1016","volume":"76","author":[{"given":"Ingrid F.","family":"Metzger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Quigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulateef O.","family":"Aregbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Thong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Flockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen K.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeruesenay","family":"Desta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.curtheres.2014.05.002_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"issue":"9239","key":"10.1016\/j.curtheres.2014.05.002_bib2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.curtheres.2014.05.002_bib3","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1086\/313859","article-title":"Management of the adverse effects of antiretroviral therapy and medication adherence","volume":"30","author":"Max","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2014.05.002_bib4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available at http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. 2013."},{"issue":"10","key":"10.1016\/j.curtheres.2014.05.002_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00002018-200629100-00004","article-title":"Neuropsychiatric complications of antiretroviral therapy","volume":"29","author":"Cespedes","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.curtheres.2014.05.002_bib6","unstructured":"Sustiva (efavirenz) full prescribing Information. May 2013. 1-12-2011. Bristol-Myers Squibb Company."},{"issue":"7","key":"10.1016\/j.curtheres.2014.05.002_bib7","first-page":"343","article-title":"Hepatotoxicity in patients prescribed efavirenz or nevirapine","volume":"13","author":"Bruck","year":"2008","journal-title":"Eur J Med Res"},{"issue":"8","key":"10.1016\/j.curtheres.2014.05.002_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00365548.2013.773067","article-title":"Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects","volume":"45","author":"Leutscher","year":"2013","journal-title":"Scand J Infect Dis"},{"issue":"11","key":"10.1016\/j.curtheres.2014.05.002_bib9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e328353b047","article-title":"Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals","volume":"26","author":"Scourfield","year":"2012","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.curtheres.2014.05.002_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1468-1293.2010.00831.x","article-title":"Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth","volume":"11","author":"Sikora","year":"2010","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.curtheres.2014.05.002_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/clpt.2012.34","article-title":"Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo","volume":"92","author":"Meyer zu","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2014.05.002_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3851\/IMP1502","article-title":"Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D","volume":"15","author":"Brown","year":"2010","journal-title":"Antivir Ther"},{"issue":"12","key":"10.1016\/j.curtheres.2014.05.002_bib13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0b013e32833c3281","article-title":"Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase","volume":"24","author":"Welz","year":"2010","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.curtheres.2014.05.002_bib14","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1124\/mol.108.053660","article-title":"Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells","volume":"75","author":"Ellfolk","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.curtheres.2014.05.002_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e31821ae418","article-title":"Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States","volume":"57","author":"Adeyemi","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.curtheres.2014.05.002_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood.V91.1.301","article-title":"Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project","volume":"91","author":"Sullivan","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.curtheres.2014.05.002_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-1293.2007.00500.x","article-title":"Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy","volume":"8","author":"Curkendall","year":"2007","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.curtheres.2014.05.002_bib18","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/01.aids.0000226970.04504.a8","article-title":"Haemolytic anaemia associated with efavirenz","volume":"20","author":"Freercks","year":"2006","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.curtheres.2014.05.002_bib19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":"Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial","volume":"53","author":"Swaminathan","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.curtheres.2014.05.002_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1468-1293.2006.00348.x","article-title":"HIV-related neutropaenia exacerbated by efavirenz","volume":"7","author":"Healy","year":"2006","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.curtheres.2014.05.002_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2011.249","article-title":"Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers","volume":"91","author":"Michaud","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2014.05.002_bib22","article-title":"Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent","author":"Michaud","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"10.1016\/j.curtheres.2014.05.002_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.47102\/annals-acadmedsg.V41N12p559","article-title":"Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz","volume":"41","author":"Lee","year":"2012","journal-title":"Ann Acad Med Singapore"},{"issue":"5","key":"10.1016\/j.curtheres.2014.05.002_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/clpt.2012.143","article-title":"Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification","volume":"92","author":"Iusuf","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.curtheres.2014.05.002_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.curtheres.2014.05.002_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425255.2012.685237","article-title":"Role of CAR and PXR in xenobiotic sensing and metabolism","volume":"8","author":"Wang","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"13","key":"10.1016\/j.curtheres.2014.05.002_bib27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","article-title":"Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR","volume":"62","author":"Tolson","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.curtheres.2014.05.002_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1528-1157.1989.tb05478.x","article-title":"Serum bilirubin levels with antiepileptic drugs","volume":"30","author":"Gough","year":"1989","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.curtheres.2014.05.002_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jhep.2005.09.011","article-title":"Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin","volume":"44","author":"Ellis","year":"2006","journal-title":"J Hepatol"},{"issue":"26","key":"10.1016\/j.curtheres.2014.05.002_bib30","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM196612292752602","article-title":"Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital","volume":"275","author":"Yaffe","year":"1966","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.curtheres.2014.05.002_bib31","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.105.098160","article-title":"Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor","volume":"317","author":"Faucette","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.curtheres.2014.05.002_bib32","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2013.04.002","article-title":"Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors","volume":"85","author":"Sharma","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"10.1016\/j.curtheres.2014.05.002_bib33","doi-asserted-by":"crossref","first-page":"16943","DOI":"10.1016\/S0021-9258(18)41876-5","article-title":"Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis","volume":"267","author":"Crawford","year":"1992","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.curtheres.2014.05.002_bib34","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.curtheres.2014.05.002_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1067\/mcp.2002.121424","article-title":"The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers","volume":"71","author":"Aarnoutse","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.curtheres.2014.05.002_bib36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00003088-200544100-00003","article-title":"Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir","volume":"44","author":"Le","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.curtheres.2014.05.002_bib37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"Pt 1","key":"10.1016\/j.curtheres.2014.05.002_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/bj3270305","article-title":"ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2","volume":"327","author":"Jedlitschky","year":"1997","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.curtheres.2014.05.002_bib39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1525-1497.2005.0094.x","article-title":"Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels","volume":"20","author":"Thavendiranathan","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.curtheres.2014.05.002_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.1942.02830060001001","article-title":"Rate of hemoglobin regeneration in blood donors","volume":"118","author":"Fowler","year":"1942","journal-title":"JAMA"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X14000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X14000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T17:25:37Z","timestamp":1689528337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X14000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":40,"alternative-id":["S0011393X14000095"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2014.05.002","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}